American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Virginia: American Psychiatric Association.Google Scholar

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Virginia: American Psychiatric Association.Google Scholar

Anthony, J. C., Warner, L. A., and Kessler, R. C. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol, 2, 244–268.Google Scholar

Asbridge, M., Hayden, J. A., and Cartwright, J. L. (2012). Acute cannabis consumption and motor vehicle collision risk: Systematic review of observational studies and meta-analysis. BMJ, 344, e536.Google Scholar

Azofeifa, A., Mattson, M. E., Schauer, G., et al. (2016). National estimates of marijuana use and related indicators: National Survey on Drug Use and Health, United States, 2002–2014. Morbid Mortal Week Rep (MMWR), 65, 1–28.Google Scholar

Benedetti, E., Resce, G., Brunori, P., et al. (2021). Cannabis policy changes and adolescent cannabis use: Evidence from Europe. Int J Environ Res Public Health, 18, 5174.Google Scholar

Bollom, A., Austrie, J., Hirsch, W., et al. (2018). Emergency department burden of nausea and vomiting associated with cannabis use disorder: US trends from 2006 to 2013. J Clin Gastroenterol, 52, 778–783.Google Scholar

Bonn-Miller, M. O., Harris, A. H., and Trafton, J. A. (2012). Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009. Psychol Serv, 9, 404–416.Google Scholar

Brady, J. E., and Li, G. (2014). Trends in alcohol and other drugs detected in fatally injured drivers in the United States, 1999–2010. Am J Epidemiol, 179, 692–699.CrossRefGoogle Scholar

Carliner, H., Mauro, P. M., Brown, Q. L., et al. (2017). The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002–2014. Drug Alcohol Depend, 170, 51–58.Google Scholar

Centers for Disease Control and Prevention. (2015). International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). Available at: www.cdc.gov/nchs/icd/icd9cm.htm (Last accessed 17 October 2021).Google Scholar

Centers for Disease Control and Prevention. (2021). International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM). Available at: www.cdc.gov/nchs/icd/icd10cm.htm (Last accessed 17 October 2021).Google Scholar

Chan, G., Chiu, V., Sun, T., et al. (2021). Age-related trends in cannabis use in Australia. Findings from a series of large nationally representative surveys. Addict Behav, 123, 107059.Google Scholar

Charilaou, P., Agnihotri, K., Garcia, P., et al. (2017). Trends of cannabis use disorder in the inpatient: 2002 to 2011. Am J Med, 130, 678–687 e7.CrossRefGoogle ScholarPubMed

Compton, W. M., Grant, B. F., Colliver, J. D., et al. (2004). Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA, 291, 2114–2121.Google Scholar

Compton, W. M., Han, B., Jones, C. M., et al. (2016). Marijuana use and use disorders in adults in the USA, 2002–14: Analysis of annual cross-sectional surveys. Lancet Psychiatry, 3, 954–964.Google Scholar

Compton, W. M., Han, B., Jones, C. M., et al. (2019). Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. Drug Alcohol Depend, 204, 107468.CrossRefGoogle ScholarPubMed

Degenhardt, L., & Hall, W. (2012). Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet, 379, 55–70.Google Scholar

Denis, C. M., Gelernter, J., Hart, A. B., et al. (2015). Inter-observer reliability of DSM-5 substance use disorders. Drug Alcohol Depend, 153, 229–235.Google Scholar

Englund, A., Freeman, T. P., Murray, R. M., et al. (2017). Can we make cannabis safer? Lancet Psychiatry, 4, 643–648.Google Scholar

Gajendran, M., Sifuentes, J., Bashashati, M., et al. (2020). Cannabinoid hyperemesis syndrome: Definition, pathophysiology, clinical spectrum, insights into acute and long-term management. J Invest Med, 68, 1309–1316.Google Scholar

Ghasemiesfe, M., Ravi, D., Vali, M., et al. (2018). Marijuana use, respiratory symptoms, and pulmonary function: A systematic review and meta-analysis. Ann Intern Med, 169, 106–115.CrossRefGoogle ScholarPubMed

Goodman, S., Wadsworth, E., Leos-Toro, C., et al. (2020). Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets. Int J Drug Policy, 76, 102658.Google Scholar

Grant, B. F. (1996). Prevalence and correlates of drug use and DSM-IV drug dependence in the United States: Results of the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse, 8, 195–210.Google Scholar

Grant, B. F. (1997). Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: Results of the National Longitudinal Alcohol Epidemiologic Survey. J Stud Alcohol, 58, 464–473.Google Scholar

Grant, B. F., Chu, A., Sigman, R., et al. (2014). Source and Accuracy Statement: National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism. Available at: www.niaaa.nih.gov/sites/default/files/NESARC_Final_Report_FINAL_1_8_15.pdf (Last accessed 10 October 2021).Google Scholar

Grant, B. F., Goldstein, R. B., Saha, T. D., et al. (2015a). Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry, 72, 757–766.Google Scholar

Grant, B. F., Goldstein, R. B., Smith, S. M., et al. (2015b). The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): Reliability of substance use and psychiatric disorder modules in a general population sample. Drug Alcohol Depend, 148, 27–33.Google Scholar

Grant, B. F., Moore, T. C., Shepard, J., et al. (2003). Source and Accuracy Statement: Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism.Google Scholar

Grant, B. F., Stinson, F. S., Dawson, D. A., et al. (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry, 61, 807–816.Google Scholar

Grucza, R. A., Agrawal, A., Krauss, M. J., et al. (2016a). Declining prevalence of marijuana use disorders among adolescents in the United States, 2002 to 2013. J Am Acad Child Adolesc Psychiatry, 55, 487–494 e6.Google Scholar

Grucza, R. A., Agrawal, A., Krauss, M. J., et al. (2016b). Recent trends in the prevalence of marijuana use and associated disorders in the United States. JAMA Psychiatry, 73, 300–301.Google Scholar

Gutkind, S., Fink, D. S., Shmulewitz, D., et al. Psychosocial and health problems associated with alcohol use disorder and cannabis use disorder in U.S. adults. Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109137.Google Scholar

Hall, W., and Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. Lancet, 374, 1383–1391.Google Scholar

Han, B., Compton, W. M., Jones, C. M., et al. (2017). Cannabis use and cannabis use disorders among youth in the United States, 2002–2014. J Clin Psychiatry, 78, 1404–1413.CrossRefGoogle ScholarPubMed

Hartman, R. L., Brown, T. L., Milavetz, G., et al. (2015) Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend, 154, 25–37.Google Scholar

Hartman, R. L., and Huestis, M. A. (2013). Cannabis effects on driving skills. Clin Chem, 59, 478–492.Google Scholar

Hasin, D., Samet, S., Nunes, E., et al. (2006). Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry, 163, 689–696.Google Scholar

Hasin, D., Shmulewitz, D., Stohl, M., et al. (2020). Test–retest reliability of DSM-5 substance disorder measures as assessed with the PRISM-5, a clinician-administered diagnostic interview. Drug Alcohol Depend, 216, 108294.Google Scholar

Hasin, D. S., and Aharonovich, E. (2020). Implications of medical and recreational marijuana laws for neuroscience research: A review. Curr Behav Neurosci Rep, 7, 258–266.Google Scholar

Hasin, D. S., Greenstein, E., Aivadyan, C., et al. (2015a) The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): Procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample. Drug Alcohol Depend, 148, 40–46.Google Scholar

Hasin, D. S., Kerridge, B. T., Saha, T. D., et al. (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Am J Psychiatry, 173, 588–599.Google Scholar

Hasin, D. S., O’Brien, C. P., Auriacombe, M., et al. (2013). DSM-5 criteria for substance use disorders: Recommendations and rationale. Am J Psychiatry, 170, 834–851.Google Scholar

Hasin, D. S., Saha, T. D., Kerridge, B. T., et al. (2015b). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 72, 1235–1242.Google Scholar

Johnston, L. D., Miech, R. A., O’Malley, P. M., et al. (2020). Demographic Subgroup Trends among Adolescents in the Use of Various Licit and Illicit Drugs, 1975–2019. Ann Arbor, MI: Institute for Social Research, University of Michigan. Available at: www.monitoringthefuture.org/pubs/occpapers/mtf-occ94.pdf (Last accessed 17 October 2021).Google Scholar

Kerr, W. C., Lui, C., and Ye, Y. (2018). Trends and age, period and cohort effects for marijuana use prevalence in the 1984–2015 US National Alcohol Surveys. Addiction, 113, 473–481.Google Scholar

Koob, G. F., and Le Moal, M. (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24, 97–129.Google Scholar

Lenne, M. G., Dietze, P. M., Triggs, T. J., et al. (2010). The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. Accid Anal Prev, 42, 859–866.Google Scholar

Leung, J., Chan, G. C. K., Hides, L., et al. (2020). What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addict Behav, 109, 106479.Google Scholar

Li, M. C., Brady, J. E., DiMaggio, C. J., et al. (2012). Marijuana use and motor vehicle crashes. Epidemiol Rev, 34, 65–72.Google Scholar

Livne, O., Shmulewitz, D., Lev-Ran, S., et al. (2019). DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug Alcohol Depend, 195, 170–177.Google Scholar

Manthey, J. (2019). Cannabis use in Europe: Current trends and public health concerns. Int J Drug Policy, 68, 93–96.Google Scholar

McKay, M. P., and Groff, L. (2016). 23 years of toxicology testing fatally injured pilots: Implications for aviation and other modes of transportation. Accid Anal Prev, 90, 108–117.Google Scholar

Miech, R. A., Johnston, L. D., O’Malley, P. M., et al. (2021). Monitoring the Future National Survey Results on Drug Use, 1975–2020: Volume I, Secondary School Students. Ann Arbor, MI: Institute for Social Research, University of Michigan. Available at: www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2020.pdf (Last accessed 17 October 2021).Google Scholar

Miech, R. A., Patrick, M. E., O’Malley, P. M., et al. (2020). Trends in reported marijuana vaping among US adolescents, 2017–2019. JAMA, 323, 475–476.Google Scholar

Millar, S. R., Mongan, D., O’Dwyer, C., et al. (2021). Correlates of patterns of cannabis use, abuse and dependence: Evidence from two national surveys in Ireland. Eur J Public Health, 31, 441–447.Google Scholar

National Institute on Drug Abuse. (2021). Monitoring the Future. Available at: www.drugabuse.gov/drug-topics/trends-statistics/monitoring-future (Last accessed 18 October 2021).Google Scholar

Naveed, S., Waqas, A., Chaudhary, A. M. D., et al. (2020). Prevalence of common mental disorders in south Asia: A systematic review and meta-regression analysis. Frontiers in Psychiatry, 11, 573150.Google Scholar

O’Neill-Dee, C., Spiller, H. A., Casavant, M. J., et al. (2020). Natural psychoactive substance-related exposures reported to United States poison control centers, 2000–2017. Clin Toxicol, 58, 813–820.Google Scholar

OECD and The World Bank. (2020). Health at a Glance: Latin America and the Caribbean 2020. Available at: www.oecd-ilibrary.org/content/publication/6089164f-en (Last accessed 22 October 2021).Google Scholar

Public Health England, Home Office, Welsh Government, The Scottish Government, Public Health Wales & Department of Health (Northern Ireland). (2021). United Kingdom Drug Situation: Focal Point annual report. Available at: www.gov.uk/government/publications/united-kingdom-drug-situation-focal-point-annual-report (Last accessed 22 October 2021).Google Scholar

Richards, J. R. (2018). Cannabinoid hyperemesis syndrome: Pathophysiology and treatment in the emergency department. J Emerg Med, 54, 354–363.Google Scholar

Rigucci, S., Marques, T. R., Di Forti, M., et al. (2016). Effect of high-potency cannabis on corpus callosum microstructure. Psychol Med, 46, 841–854.Google Scholar

Rogeberg, O., and Elvik, R. (2016). The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addiction, 111, 1348–1359.Google Scholar

Santaella-Tenorio, J., Levy, N. S., Segura, L. E., et al. (2019). Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002–2016. Drug Alcohol Depend, 205, 107621.Google Scholar

Sarvet, A. L., Wall, M. M., Keyes, K. M., et al. (2018). Recent rapid decrease in adolescents’ perception that marijuana is harmful, but no concurrent increase in use. Drug Alcohol Depend, 186, 68–74.Google Scholar

Shi, Y. (2017). Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever. Drug Alcohol Depend, 173, 144–150.CrossRefGoogle ScholarPubMed

Singh, J. A. (2022). Time-trends in hospitalizations with cannabis use disorder: A 17-year U.S. national study. Subst Abus, 43, 408–414.Google Scholar

Sofuoglu, M., Sugarman, D. E., and Carroll, K. M. (2010). Cognitive function as an emerging treatment target for marijuana addiction. Exp Clin Psychopharmacol, 18, 109–119.Google Scholar

Strand, M. C., Gjerde, H., and Morland, J. (2016). Driving under the influence of non-alcohol drugs: An update. Part II: Experimental studies. Forensic Sci Rev, 28, 79–101.Google Scholar

Substance Abuse and Mental Health Services Administration. (2020). 2019 NSDUH Detailed Tables. Available at: www.samhsa.gov/data/report/2019-nsduh-detailed-tables (Last accessed 15 October 2021).Google Scholar

United Nations Office on Drugs and Crime. (2020). UNODC World Drug Report 2020: Global Drug Use Rising; while COVID-19 Has Far Reaching Impact on Global Drug Markets. Vienna: United Nations Office on Drugs and Crime.Google Scholar

United Nations Office on Drugs and Crime. (2021). World Drug Report 2021. Available at: www.unodc.org/res/wdr2021/field/WDR21_Booklet_3.pdf (Last accessed 17 October 2021).Google Scholar

University of Michigan. (2021). Monitoring the Future. Available at: www.monitoringthefuture.org/ (Last accessed 17 October 2021).Google Scholar

Volkow, N. D., Swanson, J. M., Evins, A. E., et al. (2016). Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry, 73, 292–297.Google Scholar

Wadsworth, E., and Hammond, D. (2019). International differences in patterns of cannabis use among youth: Prevalence, perceptions of harm, and driving under the influence in Canada, England & United States. Addict Behav, 90, 171–175.CrossRefGoogle ScholarPubMed

Watson, T. M., and Mann, R. E. (2016). International approaches to driving under the influence of cannabis: A review of evidence on impact. Drug Alcohol Depend, 169, 148–155.CrossRefGoogle ScholarPubMed

World Health Organization. (2016). International Statistical Classification of Diseases and Related Health Problems, 10th ed. Available at: https://icd.who.int/browse10/2016/en (Last accessed 15 October 2021).Google Scholar

World Health Organization. (2021). Cannabis. Available at: www.who.int/teams/mental-health-and-substance-use/alcohol-drugs-and-addictive-behaviours/drugs-psychoactive/cannabis (Last accessed 17 October 2021).Google Scholar

Zhu, H., and Wu, L. T. (2016). Trends and correlates of cannabis-involved emergency department visits: 2004 to 2011. J Addict Med, 10, 429–436.Google Scholar

Arterberry, B. J., Padovano, H. T., Foster, K. T., et al. (2019). Higher average potency across the United States is associated with progression to first cannabis use disorder symptom. Drug Alcohol Depend, 195, 186–192.Google Scholar

Barrus, D. G., Capogrossi, K. L., Cates, S. C., et al. (2016). Tasty THC: Promises and challenges of cannabis edibles. Methods Rep RTI Press, 10.3768.Google Scholar

Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., et al. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36, 1219–1226.Google Scholar

Budney, A. J., Sargent, J. D., and Lee, D. C. (2015). Vaping cannabis (marijuana): Parallel concerns to e-cigs? Addiction, 110, 1699–1704.Google Scholar

Burgdorf, J. R., Kilmer, B., and Pacula, R. L. (2011). Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend, 117, 59–61.Google Scholar

Chandra, S., Radwan, M. M., Majumdar, C. G., et al. (2019). New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci, 269, 5–15.Google Scholar

Chouvy, P.-A., and Afsahi, K. (2014). Hashish revival in Morocco. Int J Drug Policy, 25, 416–423.Google Scholar

Craft, S., Winstock, A., Ferris, J., et al. (2020). Characterising heterogeneity in the use of different cannabis products: Latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. Psychol Med, 50, 2364–2373.Google Scholar

Curran, V. H., Brignell, C., Fletcher, S., et al. (2002). Cognitive and subjective dose–response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology, 164, 61–70.Google Scholar

D’Souza, D. C., Perry, E., MacDougall, L., et al. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology, 29, 1558–1572.Google Scholar

Davenport, S. (2021). Price and product variation in Washington’s recreational cannabis market. Int J Drug Policy, 91, 102547.Google Scholar

De Meijer, E. P., Bagatta, M., Carboni, A., et al. (2003). The inheritance of chemical phenotype in Cannabis sativa L. Genetics, 163, 335–346.Google Scholar

Di Forti, M., Marconi, A., Carra, E., et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. Lancet Psychiatry, 2, 233–238.Google Scholar

Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.Google Scholar

Di Forti, M., Sallis, H., Allegri, F., et al. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull, 40, 1509–1517.Google Scholar

Dujourdy, L., and Besacier, F. (2017). A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sci Int, 272, 72–80.Google Scholar

ElSohly, M. A., Chandra, S., Radwan, M., et al. (2021). A comprehensive review of cannabis potency in the United States in the last decade. Biol Psychiatry: Cogn Neurosci Neuroimag, 6, 603–606.Google Scholar

ElSohly, M. A., Mehmedic, Z., Foster, S., et al. (2016). Changes in cannabis potency over the last 2 decades (1995–2014): Analysis of current data in the United States. Biol Psychiatry, 79, 613–619.Google Scholar

EMCDDA. (2019). European Monitoring Centre for Drugs and Drug Addiction. Developments in the European Cannabis Market. Lisbon: EMCDDA Papers, Issue.Google Scholar

Freeman, A. M., Petrilli, K., Lees, R., et al. (2019). How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review. Neurosci Biobehav Rev, 107, 696–712.Google Scholar

Freeman, T., and Winstock, A. (2015). Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med, 45, 3181–3189.Google Scholar

Freeman, T. P., Craft, S., Wilson, J., et al. (2021). Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: Systematic review and meta‐analysis. Addiction, 116, 1000–1010.Google Scholar

Freeman, T. P., Groshkova, T., Cunningham, A., et al. (2019). Increasing potency and price of cannabis in Europe, 2006–16. Addiction, 114, 1015–1023.Google Scholar

Freeman, T. P., Hindocha, C., Baio, G., et al. (2020). Cannabidiol for the treatment of cannabis use disorder: A phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry, 7, 865–874.Google Scholar

Freeman, T. P., and Lorenzetti, V. (2020). ‘Standard THC units’: A proposal to standardize dose across all cannabis products and methods of administration. Addiction, 115, 1207–1216.Google Scholar

Freeman, T. P., Morgan, C. J., Hindocha, C., et al. (2014). Just say ‘know’: How do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction, 109, 1686–1694.Google Scholar

Freeman, T. P., van der Pol, P., Kuijpers, W., et al. (2018). Changes in cannabis potency and first-time admissions to drug treatment: A 16-year study in the Netherlands. Psychol Med, 48, 2346–2352.Google Scholar

Hines, L. A., Freeman, T. P., Gage, S. H., et al. (2020). Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiatry, 77, 1044–1051.Google Scholar

Hurd, Y. L., Spriggs, S., Alishayev, J., et al. (2019). Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry, 176, 911–922.Google Scholar

Jikomes, N., and Zoorob, M. (2018). The cannabinoid content of legal cannabis in Washington State varies systematically across testing facilities and popular consumer products. Sci Rep, 8, 4519.Google Scholar

Leung, J., Stjepanović, D., Dawson, D., et al. (2021). Do cannabis users reduce their THC dosages when using more potent cannabis products? A review. Front Psychiatry, 12, 163.Google Scholar

Leweke, F., Piomelli, D., Pahlisch, F., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translat Psychiatry, 2, e94.Google Scholar

Loflin, M., and Earleywine, M. (2014). A new method of cannabis ingestion: The dangers of dabs? Addict Behav, 39, 1430–1433.Google Scholar

Mahamad, S., Wadsworth, E., Rynard, V., et al. (2020). Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalisation. Drug Alcohol Rev, 39, 337–346.Google Scholar

McGuire, P., Robson, P., Cubala, W. J., et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. Am J Psychiatry, 175, 225–231.Google Scholar

Meacher, M., Nutt, D., Liebling, J., et al. (2019). Should the supply of cannabis be legalised now? BMJ, 366, l4473.Google Scholar

Mehmedic, Z., Chandra, S., Slade, D., et al. (2010). Potency trends of Δ9‐THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci, 55, 1209–1217.Google Scholar

Meier, M. H. (2017). Associations between butane hash oil use and cannabis-related problems. Drug Alcohol Depend, 179, 25–31.Google Scholar

NIDA. (2021). Establishing 5 mg of THC as the Standard Unit for Research. Available at: https://nida.nih.gov/about-nida/noras-blog/2021/05/establishing-5mg-thc-standard-unit-research. Last accessed 18 March 2022.Google Scholar

Niesink, R. J., Rigter, S., Koeter, M. W., et al. (2015). Potency trends of Δ9‐tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15. Addiction, 110, 1941–1950.Google Scholar

Pijlman, F., Rigter, S., Hoek, J., et al. (2005). Strong increase in total delta‐THC in cannabis preparations sold in Dutch coffee shops. Addict Biol, 10, 171–180.Google Scholar

Pitts, J., O’Neil, P., and Leggo, K. (1990). Survey variation in the THC content of illicitly imported cannabis* products: 1984–1989. J Pharm Pharmacol, 42, 817–820.Google Scholar

van der Pol, P., Liebregts, N., Brunt, T., et al. (2014). Cross‐sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: An ecological study. Addiction, 109, 1101–1109.Google Scholar

Potter, D. J., Clark, P., and Brown, M. B. (2008). Potency of Δ9–THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. J Forensic Sci, 53, 90–94.Google Scholar

Potter, D. J., Hammond, K., Tuffnell, S., et al. (2018). Potency of Δ9–tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. Drug Test Anal, 10, 628–635.Google Scholar

Poulsen, H., and Sutherland, G. (2000). The potency of cannabis in New Zealand from 1976 to 1996. Sci Justice, 40, 171–176.Google Scholar

Rømer Thomsen, K., Lindholst, C., Thylstrup, B., et al. (2019). Changes in the composition of cannabis from 2000–2017 in Denmark: Analysis of confiscated samples of cannabis resin. Exp Clin Psychopharmacol, 27, 402.Google Scholar

Schoeler, T., Petros, N., Di Forti, M., et al. (2016). Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study. Lancet Psychiatry, 3, 947–953.Google Scholar

Sevigny, E. L. (2013). Is today’s marijuana more potent simply because it’s fresher? Drug Test Anal, 5, 62–67.Google Scholar

Smart, R., Caulkins, J. P., Kilmer, B., et al. (2017). Variation in cannabis potency and prices in a newly legal market: Evidence from 30 million cannabis sales in Washington state. Addiction, 112, 2167–2177.Google Scholar

Taura, F., Sirikantaramas, S., Shoyama, Y., et al. (2007). Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa. FEBS Lett, 581, 2929–2934.Google Scholar

United Nations Office on Drugs and Crime. (2009). Recommended Methods for the Identification and Analysis of Cannabis and Cannabis Products (revised and updated): Manual for Use By National Drug Analysis Laboratories. New York: United Nations Publications.Google Scholar

Vandrey, R., Raber, J. C., Raber, M. E., et al. (2015). Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA, 313, 2491–2493.Google Scholar

Zamengo, L., Frison, G., Bettin, C., et al. (2014). Cannabis potency in the Venice area (Italy): Update 2013. Drug Test Anal, 7, 255–258.Google Scholar

Zuardi, A. W., Rodrigues, N. P., Silva, A. L., et al. (2017). Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol, 8, 259.CrossRefGoogle ScholarPubMed

Angrist, B., Sathananthan, G., Wilk, S., et al. (1974). Amphetamine psychosis: Behavioral and biochemical aspects. J Psychiatric Res, 11, 13–23.Google Scholar

Arseneault, L., Cannon, M., Poulton, R., et al. (2002). Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. BMJ, 325, 1212–1213.Google Scholar

Arunogiri, S., Foulds, J. A., McKetin, R., et al. (2018). A systematic review of risk factors for methamphetamine-associated psychosis. Aust NZ J Psychiatry, 52, 514–529.Google Scholar

Atkinson, D. L., and Abbott, J. K. (2018). Cannabinoids and the brain: The effects of endogenous and exogenous cannabinoids on brain systems and function. In: Compton, M. T., and Manseau, M. W. (eds.) The Complex Connection between Cannabis and Schizophrenia (pp. 37–74). San Diego: Academic Press.Google Scholar

Bell, D. S. (1973). The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry, 29, 35–40.Google Scholar

Cahill, J. D., Gupta, S., Cortes-Briones, J., et al. (2018). Psychotomimetic and cognitive effects of Δ9-Tetrahydrocannabinol in laboratory settings. In: Compton, M. T., and Manseau, M. W. (eds.) The Complex Connection between Cannabis and Schizophrenia (pp. 75–128). San Diego: Academic Press.Google Scholar

Carliner, H., Brown, Q. L., Sarvet, A. L., et al. (2017). Cannabis use, attitudes, and legal status in the U.S.: A review. Prevent Med, 104, 13–23.Google Scholar

Chan, G. C. K., and Hall, W. D. (2020). Estimation of the proportion of population cannabis consumption in Australia that is accounted for by daily users using Monte Carlo simulation. Addiction, 115, 1182–1186.Google Scholar

Connell, P. H. (1958). Amphetamine Psychosis. (Maudsley Monograph). London: Published for the Institute of Psychiatry by Chapman and Hall.Google Scholar

Connor, J. P., Stjepanović, D., Le Foll, B., et al. (2021). Cannabis use and cannabis use disorder. Nature Rev Dis Primers, 7, 16.Google Scholar

Cox, C. (2018). The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018. Health Policy, 122, 205–209.Google Scholar

Cresswell, A. (2005). Weak drug laws linked to madness. The Australian, 29 October.Google Scholar

Curran, C., Byrappa, N., and McBride, A. (2004). Stimulant psychosis: Systematic review. Br J Psychiatry, 185, 196–204.Google Scholar

Degenhardt, L., and Hall, W. D. (2001). The association between psychosis and problematical drug use among Australian adults: Findings from the National Survey of Mental Health and Well-being. Psychol Med, 31, 659–668.Google Scholar

Degenhardt, L., Hall, W. D., and Lynskey, M. (2003). Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend, 71, 37–48.Google Scholar

Dills, A., Goffard, S., Miron, J., et al. (2021). The Effect of State Marijuana Legalizations: 2021 Update. Washington, DC: Cato Institute.Google Scholar

Dwyer, T., Ponsonby, A. L., Blizzard, L., et al. (1995). The contribution of changes in the prevalence of prone sleeping position to the decline in sudden infant death syndrome in Tasmania. JAMA, 273, 783–789.Google Scholar

Faggiano, F., Minozzi, S., Versino, E., et al. (2014). Universal school-based prevention for illicit drug use. Cochrane Database Syst Rev, CD003020.Google Scholar

Fergusson, D., and Boden, J. (2008). Cannabis use and later life outcomes. Addiction, 103, 969–976; discussion 977–978.Google Scholar

Fergusson, D., Boden, J., and Horwood, L. (2006). Cannabis use and other illicit drug use: Testing the cannabis gateway hypothesis. Addiction, 101, 556–569.Google Scholar

Fergusson, D., Hall, W. D., Boden, J., et al. (2015). Rethinking cigarette smoking, cannabis use, and psychosis. Lancet Psychiatry, 2, 581–582.Google Scholar

Fergusson, D., Horwood, L., and Ridder, E. (2005). Tests of causal linkages between cannabis use and psychotic symptoms. Addiction, 100, 354–366.Google Scholar

Fergusson, D., Horwood, L., and Swain-Campbell, N. (2003). Cannabis dependence and psychotic symptoms in young people. Psychol Med, 33, 15–21.Google Scholar

Ferri, M., Allara, E., Bo, A., et al. (2013). Media campaigns for the prevention of illicit drug use in young people. Cochrane Database Syst Rev, CD009287.Google Scholar

Gage, S. H., Hickman, M., Heron, J., et al. (2014). Associations of cannabis and cigarette use with psychotic experiences at age 18: Findings from the Avon Longitudinal Study of Parents and Children. Psychol Med, 44, 3435–3444.Google Scholar

Gage, S. H., Hickman, M., and Zammit, S. (2016). Association between cannabis and psychosis: Epidemiologic evidence. Biol Psychiatry, 79, 549–556.Google Scholar

Gates, P. J., Sabioni, P., Copeland, J., et al. (2016). Psychosocial interventions for cannabis use disorder. Cochrane Database Syst Rev, 5, CD005336.Google Scholar

Gillespie, N. A., and Kendler, K. S. (2021). Use of genetically informed methods to clarify the nature of the association between cannabis use and risk for schizophrenia. JAMA Psychiatry, 78, 467–468.Google Scholar

Gilman, J. M., Sobolewski, S. M., and Eden Evins, A. (2018). Cannabis use as an independent risk factor for, or component cause of, schizophrenia and related psychotic disorders. In: Compton, M. T., and Manseau, M. W. (eds.) The Complex Connection between Cannabis and Schizophrenia (pp. 221–246). San Diego: Academic Press.Google Scholar

Glantz, S. A., Slade, J., Bero, L. A., et al. (eds.) (1996). The Cigarette Papers. Berkeley: University of California Press.Google Scholar

Greenberg, D. M., and Lee, J. W. (2001). Psychotic manifestations of alcoholism. Curr Psychiatry Rep, 3, 314–318.Google Scholar

Hall, W. D. (1997). The recent Australian debate about the prohibition on cannabis use. Addiction, 92, 1109–1115.Google Scholar

Hall, W. D., Degenhardt, L. D., and Lynskey, M. (2001). The Health and Psychological Effects of Cannabis Use. Canberra: Commonwealth Department of Health and Aged Care.Google Scholar

Hall, W. D., Degenhardt, L., and Patton, G. (2008). Cannabis abuse and dependence. In: Essau, C. A. (ed.) Adolescent Addiction: Epidemiology, Treatment and Assessment (pp. 117–148). London: Academic Press.Google Scholar

Hall, W. D., and Hando, J. (1993). Patterns of illicit psychostimulant use in Australia. In: Burrows, D., Flaherty, B. A., and MacAvoy, M. (eds.) Psychostimulant Use in Australia. Canberra: AGPS.Google Scholar

Hall, W. D., Leung, J., and Lynskey, M. (2020). The effects of cannabis use on the development of adolescents and young adults. Ann Rev Develop Psychol, 2, 461–483.Google Scholar

Hall, W. D., and Lynskey, M. (2005). Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev, 24, 39–48.Google Scholar

Hall, W. D., and Pacula, R. (2010). Cannabis Use and Dependence: Public Health and Public Policy. Cambridge: Cambridge University Press.Google Scholar

Hall, W. D., Stjepanović, D., Caulkins, J., et al. (2019). Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet, 394, 1580–1590.Google Scholar

Hasan, A., von Keller, R., Friemel, C. M., et al. (2020). Cannabis use and psychosis: A review of reviews. Eur Arch Psychiatry Clin Neurosci, 270, 403–412.Google Scholar

Henquet, C., Krabbendam, L., Spauwen, J., et al. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ, 330, 11.Google Scholar

Hindley, G., Beck, K., Borgan, F., et al. (2020). Psychiatric symptoms caused by cannabis constituents: A systematic review and meta-analysis. Lancet Psychiatry, 7, 344–353.Google Scholar

Hudak, J., Ramsey, G., and Walsh, J. (2018). Uruguay’s Cannabis Law: Pioneering a New Paradigm. Washington, DC: Center for Effective Public Management at Brookings.Google Scholar

Hunt, G. E., Siegfried, N., Morley, K., et al. (2019). Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev, 12, CD001088.Google Scholar

Hunter, A., Murray, R., Asher, L., et al. (2020). The effects of tobacco smoking, and prenatal tobacco smoke exposure, on risk of schizophrenia: A systematic review and meta-analysis. Nicotine Tobacco Res, 22, 3–10.Google Scholar

de Irala, J., Ruiz-Canela, M., and Martinez-Gonzalez, M. (2005). Causal relationship between cannabis use and psychotic symptoms or depression. Should we wait and see? A public health perspective. Med Sci Monitor, 11, RA355–358.Google Scholar

Isbell, H., Fraser, H. F., Wikler, A., et al. (1955). An experimental study of the etiology of rum fits and delirium tremens. Q J Stud Alcohol, 16, 1–33.Google Scholar

Iversen, L. (2012). How cannabis works in the human brain. In: Castle, D., Murray, R., and D’Souza, D. C. (eds.) Marijuana and Madness (pp. 1–11). Cambridge: Cambridge University Press.Google Scholar

Jones, H. J., Gage, S. H., Heron, J., et al. (2018). Association of combined patterns of tobacco and cannabis use in adolescence with psychotic experiences. JAMA Psychiatry, 75, 240–246.Google Scholar

Klein, D. F. (2006). The flawed basis for FDA post-marketing safety decisions: The example of anti-depressants and children. Neuropsychopharmacology, 31, 689–699.Google Scholar

Ksir, C., and Hart, C. L. (2016). Cannabis and psychosis: A critical overview of the relationship. Curr Psychiatry Rep, 18, 12.Google Scholar

Lappin, J. M., and Sara, G. E. (2019). Psychostimulant use and the brain. Addiction, 114, 2065–2077.Google Scholar

Lishman, W. A. (1987). Organic Psychiatry: The Psychological Consequences of Cerebral Disorder. Oxford: Blackwell Scientific.Google Scholar

Lorenzetti, V., Hoch, E., and Hall, W. (2020). Adolescent cannabis use, cognition, brain health and educational outcomes: A review of the evidence. Eur Neuropsychopharmacol, 36, 169–180.Google Scholar

MacCoun, R. J., and Reuter, P. (2001). Drug War Heresies: Learning from Other Vices, Times and Places. Cambridge: Cambridge University Press.Google Scholar

Macleod, J., Oakes, R., Copello, A., et al. (2004). Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet, 363, 1579–1588.Google Scholar

Marconi, A., Di Forti, M., Lewis, C. M., et al. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull, 42, 1262–1269.Google Scholar

McBride, N. (2003). A systematic review of school drug education. Health Educ Res, 18, 729–742.Google Scholar

McGinty, E. E., Niederdeppe, J., Heley, K., et al. (2017). Public perceptions of arguments supporting and opposing recreational marijuana legalization. Prevent Med, 99, 80–86.Google Scholar

McKetin, R., Lubman, D. I., Baker, A. L., et al. (2013). Dose-related psychotic symptoms in chronic methamphetamine users: Evidence from a prospective longitudinal study. JAMA Psychiatry, 70, 319–324.Google Scholar

Moore, T. H. M., Zammit, S., Lingford-Hughes, A., et al. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370, 319–328.Google Scholar

Mullen, J. M., Richards, J. R., and Crawford, A. T. (2020). Amphetamine Related Psychiatric Disorders. Treasure Island, FL: StatPearls Publishing.Google Scholar

Narasimha, V. L., Patley, R., Shukla, L., et al. (2019). Phenomenology and course of alcoholic hallucinosis. J Dual Diagn, 15, 172–176.Google Scholar

Norberg, M. M., Kezelman, S., and Lim-Howe, N. (2013). Primary prevention of cannabis use: A systematic review of randomized controlled trials. PLoS ONE, 8, e53187.Google Scholar

van Os, J., Bak, M., Hanssen, M., et al. (2002). Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol, 156, 319–327.Google Scholar

Pacula, R. L., Kilmer, B., Wagenaar, A. C., et al. (2014). Developing public health regulations for marijuana: Lessons from alcohol and tobacco. Am J Public Health, 104, 1021–1028.Google Scholar

Patel, R. S., Sreeram, V., Vadukapuram, R., et al. (2020). Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States nationwide inpatient cross-sectional study. Schizophr Res, 224, 40–44.Google Scholar

Patton, G. C., Coffey, C., Carlin, J. B., et al. (2002). Cannabis use and mental health in young people: Cohort study. BMJ, 325, 1195–1198.Google Scholar

Patton, G. C., Coffey, C., Lynskey, M. T., et al. (2007). Trajectories of adolescent alcohol and cannabis use into young adulthood. Addiction, 102, 607–615.Google Scholar

Pollack, H. A., and Reuter, P. (2007). The implications of recent findings on the link between cannabis and psychosis. Addiction, 102, 173–176.Google Scholar

Porath-Waller, A. J., Beasley, E., and Beirness, D. J. (2010). A meta-analytic review of school-based prevention for cannabis use. Health Educ Behav, 37, 709–723.Google Scholar

Room, R., Fischer, B., Hall, W. D., et al. (2010). Cannabis Policy: Moving beyond Stalemate. Oxford: Oxford University Press.Google Scholar

Schoeler, T., Monk, A., Sami, M. B., et al. (2016). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry, 3, 215–225.Google Scholar

Shover, C. L., and Humphreys, K. (2019). Six policy lessons relevant to cannabis legalization. Am J Drug Alcohol Abuse, 45, 698–706.Google Scholar

Single, E. W. (1989). The impact of marijuana decriminalization: An update. J Public Health Policy, 9, 456–466.Google Scholar

Smart, R., Caulkins, J. P., Kilmer, B., et al. (2017). Variation in cannabis potency and prices in a newly legal market: Evidence from 30 million cannabis sales in Washington state. Addiction, 112, 2167–2177.Google Scholar

Subritzky, T., Pettigrew, S., and Lenton, S. (2016). Issues in the implementation and evolution of the commercial recreational cannabis market in Colorado. Int J Drug Policy, 27, 1–12.Google Scholar

Voce, A., McKetin, R., Burns, R., et al. (2019). A systematic review of the symptom profile and course of methamphetamine use and psychotic symptoms profiles associated psychosis. Subst Use Misuse, 54, 549–559.Google Scholar

Winters, K. C., Mader, J., Budney, A. J., et al. (2020). Interventions for cannabis use disorder. Curr Opin Psychology, 38, 67–74.Google Scholar

Zammit, S., Allebeck, P., Andréasson, S., et al. (2002). Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. BMJ, 325, 1199–1201.Google Scholar

Zammit, S., Moore, T. H., Lingford-Hughes, A., et al. (2008). Effects of cannabis use on outcomes of psychotic disorders: Systematic review. Br J Psychiatry, 193, 357–363.Google Scholar